Clinical and radiological disease reactivation after cessation of long-term therapy with Natalizumab

International Journal of Neuroscience

Volumn 122, Issue 1, 2012, Pages 35-39

  Baumgartner, Annette ^a   Stich, Oliver ^a   Rauer, Sebastian ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cessation of therapy; Clinical neurology; Multiple sclerosis; Natalizumab; Rebound effect

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GADOLINIUM; GLATIRAMER; IMMUNOGLOBULIN; MITOXANTRONE; NATALIZUMAB; STEROID;

ABDUCENS NERVE PARALYSIS; ADOLESCENT; ADULT; ARTICLE; BRAIN DAMAGE; CASE REPORT; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEMIPARESIS; HUMAN; HYPESTHESIA; IMMUNOMODULATION; LONG TERM CARE; LOW DRUG DOSE; MALE; MELANOMA; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; OUTPATIENT DEPARTMENT; PARAPLEGIA; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENT DISEASE; RELAPSE; STEROID THERAPY; TREATMENT DURATION; TREATMENT WITHDRAWAL; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SUBSTANCE WITHDRAWAL SYNDROME; TIME; YOUNG ADULT;

EID: 83255176110     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2011.622452     Document Type: Article

References (11)

1. Lindå H, Heijne A,Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009;361:1081-7.
2. Kurtzke JF. Clinical definition for multiple sclerosis treatment trials. Ann Neurol. 1994;36:73-9.
3. Miravelle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011 Feb;68(2):186-91.
4. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW; International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15-23. (Pubitemid 36026342)
5. O'Connor PW, Goodman A, Kappos L, Lublin FD,MillerDH, Polman CH, Rudick RA, Lynn F, Panzara MA, Sandrock AW for the AFFIRM and SENTINEL investigators. Results of clinical and magnetic resonance imaging analyses following cessation of natalizumab dosing in patients with multiple sclerosis. Mult Scler. 2006;12:S17.
6. Stüve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, Cepok S, Singh MP, Tervaert JW, De Baets M, MacManus D, Miller DH, Radü EW, Cameron EM, Monson NL, Zhang S, Kim R, Hemmer B, Racke MK. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 2009;72:396-401.
7. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008;70:1150-1. (Pubitemid 351464749)
8. Fox RJ, Kappos L. Is natalizumab overshooting its rebound? Neurology. 2008;70:1073-4. (Pubitemid 351464760)
9. Schiess N,Calabresi PA.Natalizumab: bound to rebound? Neurology. 2009;72:392-3
10. Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BM, Polman CH. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol. 2010 Sep;68(3):392-5.
11. West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol. 2010 Sep;68(3): 395-9.